Preclinical Profile of BI 224436, a Novel HIV-1 Non-Catalytic-Site Integrase Inhibitor
Open accessThe DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
BI 224436 is an HIV-1 integrase inhibitor with effective antiviral activity that acts through a mechanism that is distinct from that of integrase strand transfer inhibitors (INSTIs). This 3-quinolineacetic acid derivative series was identified using an enzymatic integrase long terminal repeat (LTR) DNA 3′-processing assay. A combination of medicinal chemistry, parallel synthesis, and structure-guided drug design led to the identification of BI 224436 as a candidate for preclinical profiling. It has antiviral 50% effective concentrations (EC 50 s) of <15 nM against different HIV-1 laboratory strains and cellular cytotoxicity of >90 μM. BI 224436 also has a low, ∼2.1-fold decrease in antiviral potency in the presence of 50% human serum and, by virtue of a steep dose-response curve slope, exhibits serum-shifted EC 95 values ranging between 22 and 75 nM. Passage of virus in the presence of inhibitor selected for either A128T, A128N, or L102F primary resistance substitutions, all mapping to a conserved allosteric pocket on the catalytic core of integrase. BI 224436 also retains full antiviral activity against recombinant viruses encoding INSTI resistance substitutions N155S, Q148H, and E92Q. In drug combination studies performed in cellular antiviral assays, BI 224436 displays an additive effect in combination with most approved antiretrovirals, including INSTIs. BI 224436 has drug-like in vitro absorption, distribution, metabolism, and excretion (ADME) properties, including Caco-2 cell permeability, solubility, and low cytochrome P450 inhibition. It exhibited excellent pharmacokinetic profiles in rat (clearance as a percentage of hepatic flow [CL], 0.7%; bioavailability [ F ], 54%), monkey (CL, 23%; F , 82%), and dog (CL, 8%; F , 81%). Based on the excellent biological and pharmacokinetic profile, BI 224436 was advanced into phase 1 clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Resistance to ALLINIs maps to the IN CCD dimer interface in the vicinity of the LEDGF/p75 binding site171,173,179,182,188.”
From Structure and function of retroviral integrase (2022) · cites this paper as [188]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mosmann, T. (1983) · Journal of Immunological Methods · doi:10.1016/0022-1759(83)90303-4 · Cited by 56,104 · cited 2×
“Cytotoxicity resulting in 50% death of cells (CC50) was determined using the tetrazolium salt MTT metabolic assay (32).”
MethodColman (2022) · doi:10.1073/pnas · Cited by 4,370
Adachi, A., Gendelman, H. E., Koenig, S., Folks, T., Willey, R., Rabson, A., & Martin, M. A. (1986) · Journal of Virology · doi:10.1128/jvi.59.2.284-291.1986 · Cited by 2,834
Purification and Characterization
(2006) · Biomacromolecules · doi:10.1002/0470080124.ch3 · Cited by 2,309
Inhibitors of Strand Transfer That Prevent Integration and Inhibit HIV-1 Replication in Cells
Hazuda, D. J., Felock, P., Witmer, M., Wolfe, A., Stillmock, K., Grobler, J. A., Espeseth, A., Gabryelski, L., Schleif, W., Blau, C., et al. (2000) · Science · doi:10.1126/science.287.5453.646 · Cited by 1,131 · cited 2×
“Since the first proof of principle for the diketo acid integrase inhibitors in 2000, HIV integrase has been intensively studied as a target for drug discovery (8).”
BackgroundMethodRetroviral intasome assembly and inhibition of DNA strand transfer
Hare, S., Gupta, S. S., Valkov, E., Engelman, A., & Cherepanov, P. (2010) · Nature · doi:10.1038/nature08784 · Cited by 678
Shaw, G. M., Hahn, B. H., Arya, S. K., Groopman, J. E., Gallo, R. C., & Wong-Staal, F. (1984) · Science · doi:10.1126/science.6095449 · Cited by 633
A three-dimensional model to analyze drug-drug interactions
Prichard, M. N., & Shipman, C. (1990) · Antiviral Research · doi:10.1016/0166-3542(90)90001-n · Cited by 544 · cited 1×
“transformed with Prichard and Shipmann’s MacSynergy II software using the Bliss independence model (38).”
MethodAn essential role for LEDGF/p75 in HIV integration
Llano, M., Saenz, D. T., Meehan, A., Wongthida, P., Peretz, M., Walker, W. H., Teo, W., & Poeschla, E. M. (2006) · Science · doi:10.1126/science.1132319 · Cited by 537
LEDGF/p75 Is Essential for Nuclear and Chromosomal Targeting of HIV-1 Integrase in Human Cells
Maertens, G., Cherepanov, P., Pluymers, W., Busschots, K., De Clercq, E., Debyser, Z., & Engelborghs, Y. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303594200 · Cited by 493
Antimicrobial Agents and Chemotherapy
(2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac · Cited by 485
Christ, F., Voet, A., Marchand, A., Nicolet, S., Desimmie, B. A., Marchand, D., Bardiot, D., Van der Veken, N. J., Van Remoortel, B., Strelkov, S. V., et al. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.370 · Cited by 479 · cited 1×
“Given that the interaction between integrase and the host cell factor LEDGF has been proposed to be critical for HIV-1 viral replication, others have developed biochemical assays to probe for inhibitors of the integrase-LEDGF interaction (21, 22).”
BackgroundBushman, F. D., & Craigie, R. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.4.1339 · Cited by 410 · cited 1×
“The primary function of HIV integrase is to integrate newly synthesized viral cDNA into the host genome, which is an obligate process for viral replication (1, 2).”
BackgroundGrobler, J. A., Stillmock, K., Hu, B., Witmer, M., Felock, P., Espeseth, A. S., Wolfe, A., Egbertson, M., Bourgeois, M., Melamed, J., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.092056199 · Cited by 399
The importance of plasma protein binding in drug discovery
Trainor, G. L. (2007) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2.1.51 · Cited by 348 · cited 1×
“These cross-species differences in enterohepatic recirculation and plasma protein binding result in a degree of uncertainty with respect to the human PK and dose predictions (54).”
BackgroundDose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs
Shen, L., Peterson, S., Sedaghat, A. R., McMahon, M. A., Callender, M., Zhang, H., Zhou, Y., Pitt, E., Anderson, K. S., Acosta, E. P., et al. (2008) · Nature Medicine · doi:10.1038/nm1777 · Cited by 327 · cited 2×
“Based on IPP potential calculations {IIPCmin log [1 (Cmin/ssEC50)] } (where Cmin is the minimum concentration of drug during the dosing regimen and ssEC50 is the serumshifted EC50 of the drug in the presence of human serum) at an inhibitory quotient (IQ) of 15 to 30 (where IQ Cmin/ssEC50), BI 224436 would have an IIP…”
BackgroundResultEspeseth, A. S., Felock, P., Wolfe, A., Witmer, M., Grobler, J., Anthony, N., Egbertson, M., Melamed, J. Y., Young, S., Hamill, T., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.200139397 · Cited by 317 · cited 1×
“transfer assay was based on a previously published assay (8, 10).”
MethodLlano, M., Vanegas, M., Fregoso, O., Saenz, D., Chung, S., Peretz, M., & Poeschla, E. M. (2004) · Journal of Virology · doi:10.1128/jvi.78.17.9524-9537.2004 · Cited by 305
Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors
Doyon, L., Croteau, G., Thibeault, D., Poulin, F., Pilote, L., & Lamarre, D. (1996) · Journal of Virology · doi:10.1128/jvi.70.6.3763-3769.1996 · Cited by 295
Solution structure of the HIV-1 integrase-binding domain in LEDGF/p75
Cherepanov, P., Sun, Z.-Y. J., Rahman, S., Maertens, G., Wagner, G., & Engelman, A. (2005) · Nature Structural & Molecular Biology · doi:10.1038/nsmb937 · Cited by 235 · cited 2×
“Concomitant with these studies, this pocket also was shown to serve as the binding site for LEGDF (20).”
BackgroundJurado, K. A., Wang, H., Slaughter, A., Feng, L., Kessl, J. J., Koh, Y., Wang, W., Ballandras-Colas, A., Patel, P. A., Fuchs, J. R., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1300703110 · Cited by 203 · cited 1×
“This was shown by evaluating the formation of electron-dense HIV-1 cores by electron microscopy (43, 44, 53).”
MethodBieniasz, P. D. (1997) · The EMBO Journal · doi:10.1093/emboj/16.10.2599 · Cited by 195 · cited 1×
“3)- and CCR5-tropic (BaL) viruses (51).”
HIV-1 Integrase: Structural Organization, Conformational Changes, and Catalysis
Asante-Appiah, E., & Skalka, A. M. (1999) · Advances in Virus Research · doi:10.1016/s0065-3527(08)60306-1 · Cited by 192 · cited 1×
“The primary function of HIV integrase is to integrate newly synthesized viral cDNA into the host genome, which is an obligate process for viral replication (1, 2).”
BackgroundMultimode, Cooperative Mechanism of Action of Allosteric HIV-1 Integrase Inhibitors
Kessl, J. J., Jena, N., Koh, Y., Taskent-Sezgin, H., Slaughter, A., Feng, L., de Silva, S., Wu, L., Le Grice, S. F. J., Engelman, A., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.354373 · Cited by 182
Discovery of BI 224436, a Noncatalytic Site Integrase Inhibitor (NCINI) of HIV-1
Fader, L. D., Malenfant, E., Parisien, M., Carson, R., Bilodeau, F., Landry, S., Pesant, M., Brochu, C., Morin, S., Chabot, C., et al. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml500002n · Cited by 178
Self-citationChrist, F., Shaw, S., Demeulemeester, J., Desimmie, B. A., Marchand, A., Butler, S., Smets, W., Chaltin, P., Westby, M., Debyser, Z., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00717-12 · Cited by 176 · cited 1×
“This was shown by evaluating the formation of electron-dense HIV-1 cores by electron microscopy (43, 44, 53).”
MethodMolla, A., Vasavanonda, S., Kumar, G., Sham, H. L., Johnson, M., Grabowski, B., Denissen, J. F., Kohlbrenner, W., Plattner, J. J., Leonard, J. M., et al. (1998) · Virology · doi:10.1006/viro.1998.9383 · Cited by 171
Goethals, O., Clayton, R., Van Ginderen, M., Vereycken, I., Wagemans, E., Geluykens, P., Dockx, K., Strijbos, R., Smits, V., Vos, A., et al. (2008) · Journal of Virology · doi:10.1128/jvi.00470-08 · Cited by 168
New Class of HIV-1 Integrase (IN) Inhibitors with a Dual Mode of Action
Tsiang, M., Jones, G. S., Niedziela-Majka, A., Kan, E., Lansdon, E. B., Huang, W., Hung, M., Samuel, D., Novikov, N., Xu, Y., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.347534 · Cited by 167 · cited 1×
“Similar findings have been reported for this chemical series by our group (18), researchers at Gilead Sciences (45, 50), and for an analogous chemical series referred to as LEDGINs (23).”
ResultIntegrase, LEDGF/p75 and HIV replication
Poeschla, E. M. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-7540-5 · Cited by 165
LEDGINs inhibit late stage HIV-1 replication by modulating integrase multimerization in the virions
Desimmie, B. A., Schrijvers, R., Demeulemeester, J., Borrenberghs, D., Weydert, C., Thys, W., Vets, S., Van Remoortel, B., Hofkens, J., De Rijck, J., et al. (2013) · Retrovirology · doi:10.1186/1742-4690-10-57 · Cited by 139 · cited 1×
“This was shown by evaluating the formation of electron-dense HIV-1 cores by electron microscopy (43, 44, 53).”
MethodMarinello, J., Marchand, C., Mott, B. T., Bain, A., Thomas, C. J., & Pommier, Y. (2008) · Biochemistry · doi:10.1021/bi800791q · Cited by 137
Balakrishnan, M., Yant, S. R., Tsai, L., O’Sullivan, C., Bam, R. A., Tsai, A., Niedziela-Majka, A., Stray, K. M., Sakowicz, R., & Cihlar, T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074163 · Cited by 126 · cited 1×
“Similar findings have been reported for this chemical series by our group (18), researchers at Gilead Sciences (45, 50), and for an analogous chemical series referred to as LEDGINs (23).”
ResultVirus Evolution Reveals an Exclusive Role for LEDGF/p75 in Chromosomal Tethering of HIV
Hombrouck, A., De Rijck, J., Hendrix, J., Vandekerckhove, L., Voet, A., Maeyer, M. D., Witvrouw, M., Engelborghs, Y., Christ, F., Gijsbers, R., et al. (2007) · PLoS Pathogens · doi:10.1371/journal.ppat.0030047 · Cited by 125
Self-citationLemke, C. T., Titolo, S., von Schwedler, U., Goudreau, N., Mercier, J.-F., Wardrop, E., Faucher, A.-M., Coulombe, R., Banik, S. S. R., Fader, L., et al. (2012) · Journal of Virology · doi:10.1128/jvi.00493-12 · Cited by 124
Self-citationZolopa, A. R., Berger, D. S., Lampiris, H., Zhong, L., Chuck, S. L., Enejosa, J. V., Kearney, B. P., & Cheng, A. K. (2010) · The Journal of Infectious Diseases · doi:10.1086/650698 · Cited by 113
White, P. W., Llinàs‐Brunet, M., Amad, M., Bethell, R. C., Bolger, G. T., Cordingley, M. G., Duan, J., Garneau, M., Lagacé, L., Thibeault, D., et al. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00787-10 · Cited by 113 · cited 1×
“across species by equilibrium dialysis (40).”
Self-citationQuantitative Assays for Virus Infectivity
Johnson, V. A., Byington, R. E., & Nara, P. L. (1990) · Techniques in HIV Research · doi:10.1007/978-1-349-11888-5_4 · Cited by 108
De Luca, L., Barreca, M. L., Ferro, S., Christ, F., Iraci, N., Gitto, R., Monforte, A. M., Debyser, Z., & Chimirri, A. (2009) · ChemMedChem · doi:10.1002/cmdc.200900070 · Cited by 99 · cited 2×
“A virtual screen of the LEDGF binding pocket on integrase with follow-up profiling using an integrase-LEDGF interaction assay identified a chemical series analogous to the NCINIs, termed LEDGINs, that were optimized to exhibit low M antiviral potency (23).”
MethodResultElvitegravir: A New HIV Integrase Inhibitor
Shimura, K., & Kodama, E. N. (2009) · Antiviral Chemistry and Chemotherapy · doi:10.3851/imp1397 · Cited by 97
Hawkins, M. E., Pfieiderer, W., Mazumder, A., Pommier, Y. G., & Balis, F. M. (1995) · Nucleic Acids Research · doi:10.1093/nar/23.15.2872 · Cited by 93
Three-dimensional analysis of the synergistic cytotoxicity of ganciclovir and zidovudine
Prichard, M. N., Prichard, L. E., Baguley, W. A., Nassiri, M. R., & Shipman, C. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.6.1060 · Cited by 92
Allosteric inhibition of HIV-1 integrase activity
Engelman, A., Kessl, J. J., & Kvaratskhelia, M. (2013) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2013.04.010 · Cited by 75
Métifiot, M., Maddali, K., Naumova, A., Zhang, X., Marchand, C., & Pommier, Y. (2010) · Biochemistry · doi:10.1021/bi100130f · Cited by 68
Taganov, K. D., Cuesta, I., Daniel, R., Cirillo, L. A., Katz, R. A., Zaret, K. S., & Skalka, A. M. (2004) · Journal of Virology · doi:10.1128/jvi.78.11.5848-5855.2004 · Cited by 57 · cited 1×
“HIV-1 integrase was expressed as a hexahistidine fusion protein in BL21 bacterial cells and purified by metal-chelating chromatography on a Ni(2) column followed by SP-Sepharose ion-exchange chromatography and is based on a published purification protocol (25).”
MethodHou, Y., McGuinness, D. E., Prongay, A. J., Feld, B., Ingravallo, P., Ogert, R. A., Lunn, C. A., & Howe, J. A. (2008) · SLAS Discovery · doi:10.1177/1087057108317060 · Cited by 56
Beaulieu, P. L., Bös, M., Cordingley, M. G., Chabot, C., Fazal, G., Garneau, M., Gillard, J. R., Jolicoeur, E., LaPlante, S. R., McKercher, G., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3006788 · Cited by 52
Self-citationLeeper, S. C., Montague, B. T., Friedman, J. F., & Flanigan, T. (2010) · Journal of the International AIDS Society · doi:10.1186/1758-2652-13-s2-s3 · Cited by 49
HIV type 1 integrase inhibitors: from basic research to clinical implications.
Jegede, O., Babu, J., Santo, R. D., McColl, D. J., Weber, J., & Quiñones‐Mateu, M. E. (2008) · PubMed · Cited by 45
Zhou, G., Cummings, R. T., Hermes, J. D., & Moller, D. E. (2001) · Methods · doi:10.1006/meth.2001.1215 · Cited by 40 · cited 1×
“Efficient energy transfer between the europium cryptate and XL665 will take place only if integrase and LEDGF form a bound complex (27).”
BackgroundDudley, M. N., Blaser, J., Gilbert, D. N., & Zinner, S. H. (1990) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.34.1.98 · Cited by 29 · cited 1×
“In order to assess the compound’s potency in human blood (48, 49), the antiviral activity of BI 224436 was determined in experiments in which the cell culture medium was supplemented with 10%, 20%, 30%, 40%, or 50% human serum (HS).”
MethodPotential for New Antiretrovirals to Address Unmet Needs in the Management of HIV-1 Infection
Moyle, G. J., Gatell, J. M., Perno, C. F., Ratanasuwan, W., Schechter, M., & Tsoukas, C. M. (2008) · AIDS Patient Care and STDs · doi:10.1089/apc.2007.0136 · Cited by 28 · cited 1×
“However, with the extended life span of infected patients comes the increased likelihood of a need to change medications due to the development of viral resistance, adverse events of antiviral drugs in some patients, drug-specific toxicities, and potential drug-drug interactions with the additional medications taken b…”
BackgroundKort, R. (2010) · Journal of the International AIDS Society · doi:10.1186/1758-2652-13-s1-s5 · Cited by 21
Rajotte, D., Tremblay, S., Pelletier, A., Salois, P., Bourgon, L., Coulombe, R., Mason, S. W., Lamorte, L., Sturino, C. F., & Bethell, R. C. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00113-13 · Cited by 19
Self-citationO’Meara, J. A., Yoakim, C., Bonneau, P. R., Bös, M., Cordingley, M. G., Déziel, R., Doyon, L., Duan, J., Garneau, M., Guse, I., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050255t · Cited by 18
Self-citationNew hexahydrodiazocino-naphthyridine triones as HIV-1 integrase inhibitors: WO2008048538 A1
Cotelle, P. (2009) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543770802603577 · Cited by 3
Research works printed but not linked: 1
- SchmidtNJEmmonsRW. 1989. General principles of laboratory diagnostic methods for viral, rickettsial and chlamydial infections, p 1–35. In SchmidtNJEmmonsRW (ed), Diagnostic procedures for rickettsial and chlamydial infections, 6th ed. American Public Health Association, Washington, DC.
Cited by
Small-Molecule Inhibitors of Protein-Protein Interactions: Progressing toward the Reality
Arkin, M. R., Tang, Y., & Wells, J. A. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.09.001 · Cited by 1,065
“…BI-224436 (Boehringer-Ingelheim, Gilead), which has low nanomolar antiviral potency, LE = 0.33, and LLE = 11.5 (Table 1) (Fader et al., 2014; Fenwick et al., 2014). tBPQAs were found in an HTS designed to identify inhibitors of IN-catalyzed 30 processing of DNA; structural studies later…”
BackgroundInfluentialLesbats, P., Engelman, A. N., & Cherepanov, P. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00125 · Cited by 233
Modulation of Protein–Protein Interactions for the Development of Novel Therapeutics
Petta, I., Lievens, S., Libert, C., Tavernier, J., & De Bosscher, K. (2016) · Molecular Therapy · doi:10.1038/mt.2015.214 · Cited by 240
Block-And-Lock Strategies to Cure HIV Infection
Vansant, G., Bruggemans, A., Janssens, J., & Debyser, Z. (2020) · Viruses · doi:10.3390/v12010084 · Cited by 169
da Cunha, J., Maselli, L. M. F., Stern, A. C. B., Spada, C., & Bydlowski, S. P. (2015) · World Journal of Virology · doi:10.5501/wjv.v4.i2.56 · Cited by 167
Metadata
- Authors
- Fenwick, C., Amad, M., Bailey, M. D., Bethell, R., Bös, M., Bonneau, P., Cordingley, M., Coulombe, R., Duan, J., Edwards, P., Fader, L. D., Faucher, A.-M., Garneau, M., Jakalian, A., Kawai, S., Lamorte, L., LaPlante, S., Luo, L., Mason, S., Poupart, M.-A., Rioux, N., Schroeder, P., Simoneau, B., Tremblay, S., Tsantrizos, Y., Witvrouw, M., & Yoakim, C.
- Affiliations
- Boehringer Ingelheim (Canada) (CA)
- ORCID
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2014-06
- Volume
- 58
- Issue
- 6
- Pages
- 3233-3244
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC4068430
- OpenAlex
- W2131078522
- Cited by
- 99
- References
- 56
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 4 · 2023: 12 · 2022: 11 · 2021: 9 · 2020: 10 · 2019: 6 · 2018: 6 · 2017: 8 · 2016: 10 · 2015: 8 · 2014: 7
- FWCI
- 7.73
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- HIV-1 integrase inhibitors, integrase strand transfer inhibitors, integrase resistance mutations, allosteric pocket, antiviral activity, drug resistance, combination therapy, pharmacokinetics, ADME properties, structure-based drug design
- MeSH terms
- Animals, Cloning, Molecular, DNA, Viral, Humans, Virus Replication, HIV-1, Caco-2 Cells, Anti-HIV Agents, HIV Integrase, HIV Integrase Inhibitors, Amino Acid Substitution, Hepatocytes, Drug Resistance, Viral, Serum, Mice, Rats, Cytochrome P-450 Enzyme Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.